Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin vs crystalloid volume replacement in severe sepsis or septic shock
2008-003281-25Phase 3Active
- Sponsor
- Policlinico di Milano
- Start
- Jun 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of albumin (human) in sepsis and septic shock (2 arms), sponsored by Policlinico di Milano. Primary endpoints: 28-day overall mortality and 90-day overall mortality. Started Jun 2008; status: active.
02
Drugs
albumin (human)
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on 2008-003281-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003281-25.